Home / Going-concern warnings / Seres Therapeutics, Inc.
Filed 2025-05-07 路 Form 10-Q 路 Accession 0000950170-25-065173 micro
Price before filing: $8.55 (2025-05-06 close, split/dividend-adjusted)
Market cap at flag: $72.5M (2025-05-07) 路 Latest: $23.7M (2026-10-16)
| Window | MCRB | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -3.7% | +7.2% | -11.0% | 2025-06-06 |
| 90 days | +67.0% | +12.7% | +54.3% | 2025-08-05 |
| 180 days | +78.2% | +23.0% | +55.3% | 2025-11-03 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.